1. Home
  2. SRBK vs KYTX Comparison

SRBK vs KYTX Comparison

Compare SRBK & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRBK
  • KYTX
  • Stock Information
  • Founded
  • SRBK 1887
  • KYTX 2018
  • Country
  • SRBK United States
  • KYTX United States
  • Employees
  • SRBK N/A
  • KYTX N/A
  • Industry
  • SRBK
  • KYTX
  • Sector
  • SRBK
  • KYTX
  • Exchange
  • SRBK Nasdaq
  • KYTX NYSE
  • Market Cap
  • SRBK 109.9M
  • KYTX 92.1M
  • IPO Year
  • SRBK N/A
  • KYTX 2024
  • Fundamental
  • Price
  • SRBK $12.65
  • KYTX $2.65
  • Analyst Decision
  • SRBK
  • KYTX Strong Buy
  • Analyst Count
  • SRBK 0
  • KYTX 5
  • Target Price
  • SRBK N/A
  • KYTX $19.00
  • AVG Volume (30 Days)
  • SRBK 53.9K
  • KYTX 384.6K
  • Earning Date
  • SRBK 07-25-2025
  • KYTX 05-13-2025
  • Dividend Yield
  • SRBK 0.39%
  • KYTX N/A
  • EPS Growth
  • SRBK N/A
  • KYTX N/A
  • EPS
  • SRBK N/A
  • KYTX N/A
  • Revenue
  • SRBK $27,988,000.00
  • KYTX N/A
  • Revenue This Year
  • SRBK N/A
  • KYTX N/A
  • Revenue Next Year
  • SRBK N/A
  • KYTX N/A
  • P/E Ratio
  • SRBK N/A
  • KYTX N/A
  • Revenue Growth
  • SRBK 23.80
  • KYTX N/A
  • 52 Week Low
  • SRBK $8.94
  • KYTX $1.78
  • 52 Week High
  • SRBK $13.65
  • KYTX $16.64
  • Technical
  • Relative Strength Index (RSI)
  • SRBK 37.72
  • KYTX 59.38
  • Support Level
  • SRBK $13.12
  • KYTX $2.47
  • Resistance Level
  • SRBK $13.36
  • KYTX $2.82
  • Average True Range (ATR)
  • SRBK 0.17
  • KYTX 0.24
  • MACD
  • SRBK -0.09
  • KYTX 0.04
  • Stochastic Oscillator
  • SRBK 0.00
  • KYTX 77.63

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Share on Social Networks: